Lapatinib

Lapatinib

Catalog Number:
L002369417APE
Mfr. No.:
APE-A8218
Price:
$188
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          Lapatinib (also known as GW572016), a member of the 4-anilinoquinazoline class of kinase inhibitors, is a potent, reversible and selective small-molecule inhibitor of both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2) tyrosine kinases that inhibits recombinant EGFR and HER-2 tyrosine kinases in cell-free biochemical kinase assays with values of 50% inhibition concentration IC50 of 10.8 nmol/L and 9.3 nmol/L respectively. Lapatinib interferes with the adenosine triphosphate binding in the tyrosine kinases domains of both EGFR and HER-2 resulting in the inhibition of auto-phosphorylation and resultant downstream signaling activities (such as cellular proliferation and survival).

      • Properties
        • Alternative Name
          Tykerb;GW572016;GW-572016;GW 572016, Lapatinib tosilate hydrate; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
          CAS Number
          231277-92-2
          Molecular Formula
          C29H26ClFN4O4S
          Molecular Weight
          581.06
          Appearance
          A solid
          Purity
          99.51%
          Solubility
          ≥29.05 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Lee YC, Wang LJ, et al. "Inhibition of EGFR pathway promotes the cytotoxicity of ABT-263 in human leukemia K562 cells by blocking MCL1 upregulation." Biochem Pharmacol. 2020;178:114047. PMID:32446890
          2. Ying Z, Beronja S. "Embryonic Barcoding of Equipotent Mammary Progenitors Functionally Identifies Breast Cancer Drivers." Cell Stem Cell. 2020;S1934-5909(20)30009-6. PMID:32059806
          3. Neal Shah, Pharm.D. "Investigational Chemotherapy and Novel Pharmacokinetics for the Treatment of Cancers of the CNS." West Virginia University. 2019.
          4. Duggan BM, Foley KP, et al. "Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia." Sci Rep. 2017 May 8;7(1):1578. PMID:28484277
          5. Zhang WJ, Li Y, et al. "Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer." Cancer Lett. 2017 Feb 1;386:100-109. PMID:27864115

    We Also Recommend

    BX795

    $450

    BX795

    $220

    BX795

    $236

    EPZ-6438

    $220

    Note: If you don't receive our verification email, do the following:

  • Copyright © Amerigo Scientific. All rights reserved.